Skip to Main Content

By making it easier for patients to participate in research today, Parexel’s Decentralized Clinical Trials are defining a better pathway to the medicines of tomorrow. Decentralized Clinical Trials represent an opportunity to rethink and refresh how research studies are conducted, while keeping the patient at the heart of this emerging paradigm. Developed within our Patient Innovation Center, our flexible Decentralized Clinical Trial solutions provide both fully virtual and hybrid options, as well as side-by-side possibilities.

Our experience includes more than 70 Decentralized Clinical Trials (inclusive of home nursing visits) that are either already underway or complete, and experience in excess of 200 remote patient engagement strategies incorporated into trials (e.g., patient recruitment and retention platforms, e-visits/video dosing regimens and patient insight projects). This allows us to manage and deliver a wide range of fully virtual and hybrid approaches to Decentralized Clinical Trials, while also offering important supporting capabilities.

Parexel’s Decentralized Clinical Trials combine in-house expertise and patient/caregiver insights with the latest technologies to create bespoke strategies that can help you meet your goals. From study design through execution, we’ll help you identify and manage all technology requirements. Together, we can help ensure treatments get to the patients who need them most by making it easier for diverse populations and geographies to access research.

As sponsors continue to bring many components of studies directly to patients in their homes and their communities, Parexel seamlessly collaborates with sites to make the process as efficient as possible. As a pioneer in designing and delivering Decentralized Clinical Trials, Parexel may offer sites more study opportunities, wider access to diverse patient populations in their region and reduced dropout rates due to remote patient engagement options. In turn, Parexel can design more effective protocols based on valuable site input about their patients. And together, Parexel and our site partners are even better poised to improve the overall study experience for patients and sponsors.

Central to navigating a dynamic research landscape is the ability to harness and apply patient insights. This approach, along with global expertise in understanding the ever-changing regulatory environment, and the skills necessary to access and apply fit-for-purpose data, makes Parexel a leader in Decentralized Clinical Trials.

Drugs developed using patient-centric designs are 19% more likely to launch – 87% versus 68% for drugs developed without this approach. And, they take less time to recruit the first 100 participants, too – 4 months versus the all-trials average of 7 months.1

Connected devices, like wearables and sensors, can make it easier to collect real-time clinical data readings while enabling patients to communicate with study personnel from home. Parexel has focused on integrating the latest technological advancements, and establishing key partnerships with expert providers, to be able to identify the right devices and applications for integration into your study.

Learn more about how Parexel’s Decentralized Clinical Trials are providing increased flexibility and safety for patients.

1.The Economist Intelligence Unit. The Innovation Imperative. Available at: Accessed May 2020.

Job no. B3233-07828-07